Cladribine in MS: A Key to Slowing Aging and Protecting Brain Health
As more effective MS treatments allow patients to live longer, aging-related challenges become more apparent. Dr. Gavin Giovannoni, Professor of Neurology at Queen Mary University of London, UK, explains that aging accelerates cognitive decline and disability in MS due to reduced brain reserve and early senescence. He emphasizes that early treatment with therapies like cladribine can slow brain volume loss and improve outcomes, especially when initiated early in the disease course.
Få tillgång
Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.
- Få tillgång
- Om du redan har en profil: Logga in